The study of homology between tumor progression genes and members of retroviridae as a tool to predict target-directed therapy failure by Janaina Fernandes
HYPOTHESIS AND THEORY
published: 01 May 2015
doi: 10.3389/fphar.2015.00092
Edited by:
Jian Hui Wu,
McGill University, Canada
Reviewed by:
Jiang Liu,
University of Southern California, USA
Shulin Zhuang,
Zhejiang University, China
*Correspondence:
Janaina Fernandes,
NUMPEX-BIO, Federal University
of Rio de Janeiro, Campus Xerém,
Estrada de Xerém,
27, 21949-900 Duque de Caxias,
Rio de Janeiro, Brazil
janainaf@biof.ufrj.br
Specialty section:
This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology
Received: 21 February 2015
Accepted: 16 April 2015
Published: 01 May 2015
Citation:
Fernandes J (2015) The study
of homology between tumor
progression genes and members
of retroviridae as a tool to predict
target-directed therapy failure.
Front. Pharmacol. 6:92.
doi: 10.3389/fphar.2015.00092
The study of homology between
tumor progression genes and
members of retroviridae as a
tool to predict target-directed
therapy failure
Janaina Fernandes 1,2*
1 NUMPEX-BIO, Federal University of Rio de Janeiro, Duque de Caxias, Rio de Janeiro, Brazil, 2 Institute for Translational
Research on Health and Environment in the Amazon Region – INPeTAm, Federal University of Rio de Janeiro, Rio de Janeiro,
Brazil
Oncogenes are the primary candidates for target-directed therapy, given that they are
involved directly in the progression and resistance of tumors. However, the appearance
of point mutations can hinder the treatment of patients with these new molecules, raising
costs and the need to development new analogs that target the novel mutations. Based
on an analysis of homologies, the present study discusses the possibility of predicting
the failure of a protein as a pharmacological target, due to its similarities with retrovirus
sequences, which have extremely high mutation rates. This analysis was based on the
molecular evidence available in the literature, and widely-used and well-established PSI-
BLAST, with two iterations and maximum of 500 aligned sequences. The possibility of
predicting which newly-discovered genes involved in tumor progression would likely result
in the failure of targeted therapy, using free, simple and automated bioinformatics tools,
could provide substantial savings in the time and financial resources needed for long-term
drug development.
Keywords: target-directed therapy, oncoproteins, retrovirus, mutation rates, oncogenes, point mutation, drug
resistance
The Impact of Point Mutations of Specific Targets on Drug
Development
The resistance of cancers to chemotherapy may have a number of different determinants, which all
lead to the same outcome—an increase in mortality rates. From the perspective of the development
of new drugs, resistance may annul years of trials and the investment of millions of dollars. In some
cases, the increase in patient survival may be well below expectations (Murphy and Stordal, 2011),
and formanypatients, the treatmentmay be totally ineffective. The cost of the development of a single
drug, including clinical trials, has been estimated to reach as much as 800million dollars, although it
is likely to be even more than this, given that most companies do not disclose their operational data
(DiMasi et al., 2003; Morgan et al., 2011).
Target-directed therapy offers a new approach that has a direct inhibitive effect on the molecules
involved in the development of the cancer and its resistance to drugs (Neal and Sledge, 2014). The
best documented case of targeted therapy in cancer molecular biology is that of the Tyrosine Kinase
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inhibitors (TKIs), which target the kinase domain of the BCR-
ABL protein, which is responsible for the pathogenesis of chronic
myelogenous leukemia (CML) through the enhancement of the
proliferation and viability of myeloid cell lineage (Evans et al.,
1993). Imatinib mersylate targets the kinase domain of BCR-ABL
(Druker et al., 1996; Sawyers et al., 2002), andwas designed to bind
to the active site of the protein and block its biological activity.
This approach revolutionized the treatment of CML, although
new difficulties arose. The main drawback in target therapy is the
mutation of the target, and in this specific case, themutation of the
imatinib binding site, whichmakes 20–40% of patients resistant to
imatinib therapy (Shah et al., 2002; Azam et al., 2008). As the use
of imatinib grew, case reports on imatinib resistant CML began
to appear, indicating that the majority of resistant phenotypes are
associated with point mutations in the BCR-ABL kinase domain
(Roumiantsev et al., 2002).
The exact effects of mutations on the therapeutic efficiency of
the TKIs are determined by the type of mutation (missense or
silent) and their position in the target molecule (active site, P-
loop). A number of studies have identified critical pointmutations
in the kinase domain of the BCR-ABL protein (Elias et al., 2014).
These mutations reduce the affinity of the imatinib with its target,
and may be accompanied by the amplification of the BCR-ABL
gene (Gorre et al., 2001). Due to the clinical impact of the failure
of imatinib therapy, the mutations were identified, and a second
generation of the drug was developed to target these mutations
(Weisberg et al., 2005).
This resulted in the development of Nilotinib, Dasatinib and
Bosutinib, which improved the response in the patients, but once
again, novel mutations arose, and recently, a third generation TKI,
Ponatinib was approved (Santos et al., 2011). Treating imatinib-
resistant patients with these new generation TKIs resulted in the
appearance of compound mutations, i.e., multiple point mutations
in the same allele, rather thanmultiple clones with different muta-
tions (polyclonal mutations; Zabriskie et al., 2014). These tumor
cells present a successive acquisition of mutations, and it was
discovered that the identity of the component mutations present
in a compound mutation reflects the type of drugs to which the
patient was exposed previously (Khorashad et al., 2013).
The most frequent BCR-ABL mutation is T315I, which is
known to cause resistance to most of the available TK inhibitors.
The substitution of a threonine by an isoleucine impairs the
formation of a hydrogen bond with the TKI, thus preventing the
binding of the drug (Bose et al., 2013). Recent studies (Ferri et al.,
2015) have shown that only the third generation TKI (ponatinib)
is able to inhibit BCR-ABL with the T315I mutation. However,
even ponatinib fails when facing compound mutations (Zabriskie
et al., 2014).
A second group of drugs with a large set of in vitro and clinical
data are the kinase inhibitors that target EGFR (Giaccone and
Wang, 2011). A number studies have demonstrated the impact
of point mutations in the targets on the outcome of the disease
(Ahmed et al., 2014), as well as compoundmutations (Berge et al.,
2013), and enormous efforts have gone into the identification of
mutations and the generation of analogs through in silico studies
(Xiang et al., 2013; Banavath et al., 2014), giving rise to consecutive
generations of the drugs.
An important feature common to all these targets is their
high degree of homology with retroviral protein sequences. In
fact, many of these human oncogenes have been named after
their retroviral homologs. Examples include the human c-ABL,
which is a homolog of v-ABL—theAbelson leukemia virus (Reddy
et al., 1983), Src, a homolog of v- SRC—the Avian sarcoma virus
(Schwartz et al., 1983), human AKT, a homolog of v-AKT—the
AKT8murine leukemia virus (Staal, 1987), andKras, a homolog of
the Kirsten murine sarcoma virus (Aaronson and Weaver, 1971).
Retroviruses are known to have high mutation rates, and one
of the best documented is the mutation of the reverse tran-
scriptase gene of the Human Immunodeficiency Virus, or HIV
(García-Lerma and Heneine, 2001; Johnson et al., 2008). Due
to a lack of correction mechanisms in the reverse transcriptase
polymerization, the nucleotide substitution rate for retroviruses
may reach 10 4 substitutions per cell infection (Preston et al.,
1988), while in eukaryotes, due to their repair systems, these
values are between 3  10 8 and 5  10 11 per cell division
(Drake et al., 1998).
The present study hypothesizes that the similarity of human
oncoproteins with retroviral sequences may have a major impact
on the development of drugs for targeted therapy. In this case, the
analysis of homologies between proposed targets and retroviral
proteins may contribute to the identification of targets that are
more likely to develop resistance to drugs designed for these
targets. While the discussion of this hypothesis is based on the
data available for BCR-ABL, it is hoped that the concept can be
extended in practice to other oncogenes that present a high degree
of homology with retroviruses.
Materials and Methods
Sequence Similarity
Sequence similarity was analyzed using PSI-BLAST—the Posi-
tion Iterated-Local Alignment Search Tool (Altschul, 1997). The
human form of each protein (Homo sapiens tax ID 9606) was
aligned with those of viruses (tax ID:10239), with two iterations
and a maximum of 500 aligned sequences. Artificial sequences
and synthetic constructions were not considered for this analysis.
Statistical Analysis
Statistical significance was generated via PSI-BLAST. Amaximum
E-value of 0.001 was considered for this analysis. The lower the
E-value, the higher the homology.
Hypotheses
The Homology between Human Oncoproteins
and Retroviral Proteins
When a new protein is identified as a drug target throughmolecu-
lar biology screenings, the structuremay be elucidated by physical
methods and/or in silico modeling. The latter is based on the
identification of homologies between the target sequence and
those known to occur in proteins which native structure were
already elucidated (Floudas, 2007). Based on these results, the
proteins are grouped in homolog families. These protein families
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TABLE 1 | Viral homologies found in human oncoproteins.
Oncoprotein Accession number of
query sequence
E-value Query
coverage (%)
Taxon containing the homolog sequence Viral group
Akt NP_001014431.1 0 100 AKT8 murine leukemia virus Retroviridae
Src P12931.3 0 100 Avian sarcoma virus S1 Retroviridae
PI3K NP_006209.2 0 98 Avian sarcoma virus 16 Retroviridae
ABL NP 005148.2 0 72 Abelson murine leukemia virus Retroviridae
RAF P04049.1 0 57 IC4 retrovirus Retroviridae
EGFR NP_005219.2 0 52 Avian leukosis virus Retroviridae
ROS1 NP_002935.2 1 162 62 UR2 sarcoma virus Retroviridae
FGFR1 NP_075598.2 6 151 81 Feline sarcoma virus Retroviridae
RET P07949.3 5 146 39 UR2 sarcoma virus Retroviridae
MET NP_001120972.1 1 131 23 Avian erythroblastosis virus Retroviridae
KRAS NP_004976.2 3 122 100 Kirsten murine sarcoma virus Retroviridae
IGFR1 NP_000557.1 5 122 33 Avian sarcoma virus S1 Retroviridae
DDR NP_001945.3 2 115 38 Avian sarcoma virus S1 Retroviridae
FAK Q05397.2 5 51 28 Feline sarcoma virus Retroviridae
IRAK1 AAH54000.1 2 86 46 Acanthamoeba poliphaga mimivirus Mimiviridae (dsDNA vírus)
are formed through gene duplication (Dharia et al., 2014 and Xu
and Dumbrack, 2012).
In addition to vertical gene transfer through evolutionary pro-
cesses, horizontal gene transfer may also occur. This process is
responsible for the existence of endogenous retroviruses in the
human genome (HERVs), which are believed to represent the
footprint of ancient germ-cell retroviral infections. They would
then have been transmitted vertically from one host generation
to the next (de Parseval and Heidmann, 2005; Weiss, 2006), but
most of them cannot produce an infectious virus due to the accu-
mulation of mutations in key genes. Even so, some HERV genes
have been adapted by the host genome for specialized functions,
and some HERVs may be capable of inducing tumor progression
(Serafino et al., 2009).
Exogenous retroviruses, in particular the acute transforming
viruses, have also relied on horizontal gene transfer to acquire
modifications of cellular genes and the capability of transform-
ing animal cells. In comparison with the cellular version, viral
oncogenes present mutations and deletions that alter the activ-
ity of the protein. Oncogenes involved in the development of
human cancers were first identified in retroviruses, and for a
time, it was believed that the origin of these oncogene was the
oncoviruses. It was later revealed that the viral forms were cellular
oncogenes acquired from the host by the retrovirus (Vogt, 2012).
This discovery was based on the analysis of v-src, the viral form
of the Rous sarcoma virus, the first oncovirus discovered (Vogt,
2012). In the specific case of BCR-ABL, its viral homolog, v-
ABL, is present in the AbelsonMurine Leukemia virus (A-MuLV)
genome, which is thought to have originated from a recombina-
tion of the Muloney Murine Leukemia helper virus (M-MuLV)
with a cellular sequence (abl) of the mouse genome (Reddy et al.,
1983). As the viral version of an oncogene is a modified version
of a mammalian sequence, a high degree of homology would be
more than expected.
The search for homologies focused on the most prominent
cases currently being researched for targeted therapy drug devel-
opment, which, like BCR-ABL, belong to the tyrosine kinase
family. Using PSI-BLAST with two iterations and a maximum
of 500 sequences, the viral homologs were retrieved (Table 1).
Most of them are truncated versions of the vertebrate protein,
but they all conserve the domain necessary to transform cells.
In this analysis, the lower the E-value, the greater the homology
(Altschul, 1997).
In these and other oncogenes, mammal sequences are incor-
porated into the viral genome, and thus become subject to the
mutation rates of retroviruses. During multiple cycles of virus
infection, mutants are produced as a result of the poor fidelity
of retroviral reverse transcriptases. Mutations are also induced in
the captured sequence, altering it, and in some cases activating its
ability to transform the target cells. A question that arises here
is whether the similarities in the sequences also extend to their
mutational status?
Mutation Rates in Retroviruses and Tumors
Mutation rates (m) can be measured as substitutions per
nucleotide per cell infection (in viruses) and substitutions per
nucleotide per replication cycle in eukaryotes. The size of the
genome is also an important parameter here (Drake and Holland,
1999). A number of studies have shown that the retroviruses have
one of the highest mutation rates of all viruses (Sanjuán et al.,
2010). Sequences subject to high mutation rates provide a broad
spectrum of random mutants for adaptation to environmental
changes, which is advantageous in general (Loeb et al., 1974). The
capacity of tumors and viruses generate and select viable mutants
will be proportional to their mutation and replication rates (Fox
andLoeb, 2010).While normal cells havemutation rates of around
10 11 (Table 2), this rises to approximately 10 7 in tumor cells,
which is higher than that found in unicellular eukaryotes and
dsDNA viruses. Retroviruses have mutation rates around 10 5, in
other words, just two orders of magnitude greater than that found
in tumors, whereas the difference is of four orders of magnitude
between normal and tumor cells, and six orders of magnitude
between normal cells and retroviruses.
Despite this variation in mutation rates, functional versions of
the same oncoprotein (for example, Src) can be found in normal
(unmutated; Knoll and Drescher, 2004; Francis et al., 2015), in
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TABLE 2 | Mutation rates expressed as substitutions per nucleotide per
cell infection (in viruses) and mutations per cell division (in
eukaryotes—yeast, tumor and normal cells).
Group m Reference
dsRNA (Retroviruses)
Murine leukemia virus 3.0  10 5 Sanjuán et al. (2010)
Human T-Cell leukemia virus
type 1 (HTLV1)
1.6  10 5 Sanjuán et al. (2010)
Bovine leukemia virus 1.7  10 5 Sanjuán et al. (2010)
Human immunodeficiency virus
type 1 (HIV1)
2.4  10 5 Sanjuán et al. (2010)
Rous sarcoma virus (RSV) 1.4  10 4 Sanjuán et al. (2010)
Spleen necrosis virus (SNV) 3.7  10 5 Sanjuán et al. (2010)
dsDNA
Herpes simplex virus type 1 5.9  10 8 Sanjuán et al. (2010)
Bacteriophage T2 9.8  10 8 Sanjuán et al. (2010)
Yeast
MSH2 WT 4.8  10 10 Lang et al. (2013)
MSH2 null (repair deficient) 7.1  10 8 Lang et al. (2013)
Tumor cells
MM96L (melanoma) 2.1  10 7 Musk et al. (1996)
Normal cells 5  10 11 Drake et al. (1998)
tumors (mutated; Hong et al., 2014) and in retrovirus (truncated
and mutated; Masker et al., 2007; Vogt, 2012).
These mutation rates are reflected in the rapid emergence of
resistance to therapy in tumor cells and viruses, and it has even
been suggested that this characteristic could be exploited ther-
apeutically through lethal mutagenesis (Mutational catastrophe).
In this approach, nucleotide analogs are used to enhance the
mutation rate of a virus (Baranovich et al., 2013) and tumor cells
(Fox and Loeb, 2010) beyond the threshold of error catastrophe,
leading them to extinction (Fox and Loeb, 2010). The deleterious
effects of high mutation rates may nevertheless be counteracted
by mutational robustness, i.e., the constancy of a phenotype in the
context of deleterious mutations (Sanjuán et al., 2007). In fact, the
mutational robustness of RNA viruses is higher than that of other
viruses and may thus have a negative effect on their sensitivity to
lethal mutagenesis (Graci et al., 2012).
The constancy of the phenotype (the induction of cell trans-
formation through kinase activity) under high mutation rates, is
actually being tested continuously, given that highly homologous
sequences of the oncogenes are present in the highly proliferative
retroviruses which can successfully infect and transform normal
cells (Masker et al., 2007). In this case, if a viral sequence has a
mutation rate around six orders of magnitude higher than the
same sequence in a normal human cell, during the proliferation
of the tumor, the retroviral homologs will be mutating at a much
higher rate than a normal cell, but below the catastrophe thresh-
old. Thus, the high mutation rate, coupled with high proliferation
and the selective environment created by target directed drugs
will result in increasing adaptation, rather than extinction. From
the viewpoint of the drug discovery, then, a target that is highly
homologous with a retrovirus is likely to be resistant to drugs, and
will probably result in the failure of the drugs developed for new
targets during the first generation (Figure 1).
Targets Presenting Variable Degrees
of Homology with Retroviruses
As discussed by Fernandes et al. (2012), sequences in tumors that
are highly homologous to those of retroviruses are typical of drug
resistance, and will contain point mutations that confer resistance
on the tumors containing them. On the other hand, sequences
of tumor-suppressing genes, such as p53 and pRB, that are not
homologous to any retrovirus family, will accumulate mutations,
andmay cease to function under highmutation rates. This implies
that the degree of homology between a sequence and a viral group
may reflect its robustness.
Recent studies have identified a number of molecules as can-
didates for the development of drugs (Alamgeer et al., 2013).
These include RET (Qi et al., 2011), ROS1 (Sun et al., 2014),
c-MET (Kim et al., 2014), and DDR1 (Kim et al., 2013), all of
which are currently being trialed (Frett et al., 2014). All these
molecules present a degree of similarity with a retroviral protein
(Table 1). For example, RET is homologous with the P68 protein
of the UR2 sarcoma virus, while ROS1 is a homolog of v-Ros
from the avian UR2 sarcoma virus oncogene (Matsushime et al.,
1986). Similarly, c-MET is a homolog of v-Sea from the Avian
Erythroblastosis Virus (Smith et al., 1989), and DDR1 a homolog
of v-Src from the Avian Sarcoma Virus. In some of these cases,
resistance to targeted therapy has already been recorded (Sun
et al., 2014). However, the higher homology of one other emerging
target, IRAK1 (interleukin-1 receptor-associated kinase 1) was
found not with a retroviral sequence (Table 1), but one belonging
to a dsDNA virus (Acanthamoeba polyphaga mimivirus).
IRAK1 is involved in IL-1beta-induced NF-kappaB activation
(Chen et al., 2002), and also in the reduced apoptosis inmyelodys-
plastic syndrome (Rhyasen et al., 2013). The IRAK1 mutation
has been found in Primary effusion lymphoma (PEL), a disease
that develops in HIV-positive patients, in association with viral
infections (Yang et al., 2014). Only additional data will confirm
whether IRAK1 presents point mutations under pressure from its
inhibitors.
Could it be Possible to Predict Which Mutations
Would Appear in a Cancer Target Prior to Clinical
Evaluation?
The mutational status of a sequence is determined by its mutation
and proliferation rates. But exactly which amino acid may be
substituted in a given position (such as T315I in the case of BCR-
ABL), and its importance for the outcome of a chemotherapy
procedure, is related to selection of which particular mutation will
confer advantage (Leder et al., 2011). Human oncoproteins and
retroviral protein sequences could theoretically present similar
pattern of mutations if both sequences present the proliferation
rates and are affected by the same selection pressures. In the
case of imatinib and its analogs targeting BCR-ABL, the same
mutations are selected for, and the results may even reflect the
order in which the drugs were applied (Shah et al., 2007; Kho-
rashad et al., 2013). Obviously, highly similar sequences subject to
similar replication rates, replicated by the same genetic system and
similar selection pressures will likely present the same pattern of
mutation.
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FIGURE 1 | Similarity between retroviral and evaluated target
sequences (blue arrow) and estimated mutation rates (m) for
selected organisms (m= substitutions per nucleotide per cell
infection in viruses and per cell division in eukaryotes, i.e., yeast,
tumor and normal cells). Estimates from Sanjuán et al. (2010; pink
arrow).
As discussed above, samples obtained from patients can be
used to identify the most frequent and relevant mutations, but
the question remains as to whether it may be possible to identify
relevant mutations in a specific target during the development of
a new drug. Using an in vitro approach, Joseph et al. (2013) were
able to identify mutations that conferred resistance to second-
generation antiandrogens. The samemutations were also found in
samples from the patients being treated, corroborating the clinical
relevance of this particular mutation.
The in vitro prediction of the identity of a mutation that likely
confers resistance to a new drug without concomitant corrobora-
tion by clinical trialswould be an economically attractive prospect,
although the direct application of these results for drug develop-
ment it would be an issue. However, the possibility of providing
an inventory of potentially relevant point mutations, which could
be investigated further through in silico studies, might represent a
potentially economic strategy.
Conclusion
The interchange with evolutionary models has contributed to
the understanding of cancer as a highly complex disease. In
cancer research, the ongoing integration of molecular biology
with disciplines such as theoretical ecology (Korolev et al., 2014),
mathematics (Beerenwinkel et al., 2015), and evolutionary biology
(Greaves, 2009) has provided important practical applications for
the discovery of new drugs.
Some proteins that possess less similarity with sequences res-
ident in retroviruses and are relevant for tumor development,
are those that act suppressing cancer, as p53 and pRB. These
molecules appeared late in evolution to allow the establishment
of the multicellular organisms (Koonin and Aravind, 2002).
Those sequences are less robust since high mutation rates abro-
gate their function. As shown in Figure 1 these sequences rely
on the opposite side of oncogenes regarding similarity with
retrovirus.
Most of the targets for drug development are molecules
involved in tumor progression, exactly because these sequences
maintain their function under high mutation rates. The hypothe-
ses presented here give rise to a challenge: identify a gene that
promotes enough tumor progression to be considered a pharma-
cological target. At the same time, this sequencemust be subjected
to low mutations rate. The later feature may be reflected by its
similarity with retroviral sequences.
In the context of the present study, another consideration
arises—if it is possible to identify a point mutation that potentially
reduces the efficiency of a new drug prior to clinical trials, should
this influence the decision to develop the drug further? In other
words, should the development of the drug continue if it is known
that it will fail in some degree due to the similarity of the target
sequence with retroviral proteins?
There are good reasons to proceed, however. In the specific
case of the application of TK inhibitors to the treatment of
leukemia and lung cancer treatment as examples, diseases that
target sequences have viral homologous, one important reason is
that most patients (70–80%) respond to targeted therapy. This
represents some 246,000 leukemia patients and 1,277,500 lung
cancer patients, worldwide, each year (Ferlay et al., 2015). In
addition, the prior in vitro identification of the mutants that will
be resistant to the first generation of a drug would contribute
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to the improvement of therapeutic strategies for non-responding
patients. This would hopefully contribution to acceleration in
the inevitable development of subsequent generations of the new
drug.
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